换一批Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals.
第一作者：
Junjie,Xu
第一单位：
Key Laboratory of Endoscopic Technique Research of Zhejiang Province, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou 310016, China.
作者：
医学主题词
动物(Animals);抗肿瘤药(Antineoplastic Agents);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);碱性螺旋-环-螺旋转录因子类(Basic Helix-Loop-Helix Transcription Factors);癌, 肝细胞(Carcinoma, Hepatocellular);细胞低氧(Cell Hypoxia);细胞系, 肿瘤(Cell Line, Tumor);细胞外信号调节MAP激酶类(Extracellular Signal-Regulated MAP Kinases);Hep G2细胞(Hep G2 Cells);人类(Humans);茚满类(Indans);肝肿瘤(Liver Neoplasms);小鼠(Mice);小鼠, 近交BALB C(Mice, Inbred BALB C);小鼠, 裸(Mice, Nude);烟酰胺(Niacinamide);苯脲化合物(Phenylurea Compounds);启动区, 遗传(Promoter Regions, Genetic);原癌基因蛋白质c-akt(Proto-Oncogene Proteins c-akt);受体, 雄激素(Receptors, Androgen);STAT3转录因子(STAT3 Transcription Factor);砜类(Sulfones)
DOI
10.1038/cddis.2017.411
PMID
29022906
发布时间
2018-12-02
- 浏览0
Cell death & disease
e3095页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
